Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment  Hannah Major-Monfried, Umut Ozbek, Anne S.

Slides:



Advertisements
Similar presentations
Stephanie J. Lee, Loretta A. Williams 
Advertisements

Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-Disease  John M. Magenau,
Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease
Current Practice in Diagnosis and Treatment of Acute Graft-versus-Host Disease: Results from a Survey among German-Austrian-Swiss Hematopoietic Stem Cell.
Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant  Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,
Tumor Necrosis Factor-α Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow.
Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole  Megan R. Barajas, Kristen.
Liver Transplantation for Hepatic Graft-Versus-Host-Disease: A United Network for Organ Sharing (UNOS) Database Study  Shahrukh Hashmi, MD MPH, Timucin.
Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease
Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease  Fevzi F. Yalniz, Mehrdad Hefazi, Kristen.
Acute Graft-Versus-Host Disease in the Setting of T Cell Depletion: Validation of a New Agvhd Risk Score  Hayder Saeed, MD, Stacey Slone, MS, Swati Yalamanchi,
Daniela Ion, Kristen Stevenson, Sook-Bin Woo, Vincent T
Vancomycin-Resistant Enterococcus (VRE) Colonization and Blood Stream Infection (BSI): Prevalence, Risk Factors, and Impact on Early Clinical Outcomes.
Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker.
Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic.
CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.
Outcome of Transplantation for Myelofibrosis
Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease  Sean Robinson.
Stephanie J. Lee, Loretta A. Williams 
Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease  Areej El-Jawahri, Joseph Pidala,
Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life
Clinical Benefit of Response in Chronic Graft-versus-Host Disease
Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease  Paul J. Martin, Barry.
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing.
Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study 
Trial in Progress: Gravitas-301, a Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo with Corticosteroids (CS) for the First-Line Treatment.
Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria  Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease
A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse  Zeyad Kanaan, MD, William Tse, MD, FACP 
Jennifer Brondon, Zachary I. Willis, David J. Weber, Kimberly A. Kasow 
Geographic Distance Is Not Associated with Inferior Outcome When Using Long-Term Transplant Clinic Strategy  Brittany Knick Ragon, Carey Clifton, Heidi.
Betty K. Hamilton, Lisa Rybicki, Sally Arai, Mukta Arora, Corey S
Treatment of Severe Refractory Acute Graft-versus-Host Disease of the Gastrointestinal Tract with Campath-1H  Alessandro Busca, Franco Locatelli, Elisabetta.
Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft- Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation 
Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma:
Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.
Infection Prevention - Visitors and the Best of Intentions
A Prospective Study of Allogeneic Transplant for Older Patients with Acute Myelogenous Leukemia (AML) Indicates that Unrelated Donor Transplants are as.
Steven M. Trifilio, Judy Pi, Jayesh Mehta 
ASBMT and CBMTG Release Choosing Wisely BMT Recommendations
Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials  Shernan G. Holtan, Todd.
Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D
What is quality in a transplant program?
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation 
Competitive TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) Following Allogeneic Stem Cell Transplantation (SCT).
Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews  Emily C. Merkel, Sandra A. Mitchell,
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia/Lymphoma: The Mayo Clinic Experience 
John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos 
Immune Profiling to Predict Treatment Response from Extracorporeal Photopheresis in Graft-Versus-Host Disease  Stefan Cordes, M.D.Ph.D., Deepti Warad,
Biology of Blood and Marrow Transplantation
A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality  Margaret.
Blood and Marrow Transplant Handbook
Calcinuerin-Inhibitor (CI) Free Graft-Versus-Host Disease (GvHD) Prophylaxis: Its Effects on Magnesium, Renal Function, and the Cost of Care  Marlee Muilenburg,
Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802 by Shernan G. Holtan, Todd E. DeFor, Angela.
Biology of Blood and Marrow Transplantation
Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial 
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Praveena Narayanan, Alexandra Wolanskyj, Shawna L. Ehlers, Mark R
Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria  Madan Jagasia, Jennifer Giglia, Wichai.
Treatment versus Transplant for Challenging Hematologic Disorders
Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes.
Lawrence Chang, David Frame, Thomas Braun, Erin Gatza, David A
TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes  Sung W. Choi,
In Memoriam: E. Donnall Thomas
The Incidence and Outcomes of Oral Mucositis Among Allogeneic Stem Cell Transplantation Patients: A Systematic Review and Meta-Analysis  Hafsa Myedah.
Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-Disease  John M. Magenau,
Presentation transcript:

Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment  Hannah Major-Monfried, Umut Ozbek, Anne S. Renteria, Matthew J. Hartwell, Attaphol Pawarode, Gregory A. Yanik, Francis Ayuk, Ernst Holler, Yvonne A. Efebera, William J. Hogan, Muna Qayed, Elizabeth O. Hexner, Kitsada Wudhikarn, Matthias Wolfl, Rainer Ordemann, Stephan Mielke, Udomsak Bunworasate, Steven M. Devine, Nicolaus Kroeger, Monzr Al-Malki, Yi-Bin Chen, Andrew C. Harris, Madan Jagasia, Carrie L. Kitko, Mark R. Litzow, Franco Locatelli, Ryotaro Nakamura, Pavan Reddy, Ran Reshef, Wolf Roesler, Daniela Weber, James Ferrara, John E. Levine  Biology of Blood and Marrow Transplantation  Volume 23, Issue 3, Pages 1-3 (March 2017) DOI: 10.1016/j.bbmt.2016.12.651 Copyright © 2016 Terms and Conditions

Figure 1 Test Cohort, n = 236 (left), Validation Cohort, n = 142 (right). Biology of Blood and Marrow Transplantation 2017 23, 1-3DOI: (10.1016/j.bbmt.2016.12.651) Copyright © 2016 Terms and Conditions

Figure 2 Test Cohort, n = 236 (left), Validation Cohort, n = 142 (right). Biology of Blood and Marrow Transplantation 2017 23, 1-3DOI: (10.1016/j.bbmt.2016.12.651) Copyright © 2016 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.